Regimen produced durable response in indolent B-cell, mantle cell lymphomas Healio Combination therapy with lenalidomide plus low-dose dexamethasone and rituximab produced a high rate of durable responses in patients with rituximab-resistant, indolent B-cell and mantle cell lymphomas, according to results of a phase 2 trial. |
